These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

254 related items for PubMed ID: 29568395

  • 1. Merestinib (LY2801653) inhibits neurotrophic receptor kinase (NTRK) and suppresses growth of NTRK fusion bearing tumors.
    Konicek BW, Capen AR, Credille KM, Ebert PJ, Falcon BL, Heady GL, Patel BKR, Peek VL, Stephens JR, Stewart JA, Stout SL, Timm DE, Um SL, Willard MD, Wulur IH, Zeng Y, Wang Y, Walgren RA, Betty Yan SC.
    Oncotarget; 2018 Mar 02; 9(17):13796-13806. PubMed ID: 29568395
    [Abstract] [Full Text] [Related]

  • 2. Mechanisms of Resistance to NTRK Inhibitors and Therapeutic Strategies in NTRK1-Rearranged Cancers.
    Fuse MJ, Okada K, Oh-Hara T, Ogura H, Fujita N, Katayama R.
    Mol Cancer Ther; 2017 Oct 02; 16(10):2130-2143. PubMed ID: 28751539
    [Abstract] [Full Text] [Related]

  • 3. Foretinib Overcomes Entrectinib Resistance Associated with the NTRK1 G667C Mutation in NTRK1 Fusion-Positive Tumor Cells in a Brain Metastasis Model.
    Nishiyama A, Yamada T, Kita K, Wang R, Arai S, Fukuda K, Tanimoto A, Takeuchi S, Tange S, Tajima A, Furuya N, Kinoshita T, Yano S.
    Clin Cancer Res; 2018 May 15; 24(10):2357-2369. PubMed ID: 29463555
    [Abstract] [Full Text] [Related]

  • 4. MET-targeting antibody (emibetuzumab) and kinase inhibitor (merestinib) as single agent or in combination in a cancer model bearing MET exon 14 skipping.
    Yan SB, Um SL, Peek VL, Stephens JR, Zeng W, Konicek BW, Liu L, Manro JR, Wacheck V, Walgren RA.
    Invest New Drugs; 2018 Aug 15; 36(4):536-544. PubMed ID: 29188469
    [Abstract] [Full Text] [Related]

  • 5. Investigation of neurotrophic tyrosine kinase receptor 1 fusions and neurotrophic tyrosine kinase receptor family expression in non-small-cell lung cancer and sensitivity to AZD7451 in vitro.
    Tatematsu T, Sasaki H, Shimizu S, Okuda K, Shitara M, Hikosaka Y, Moriyama S, Yano M, Brown J, Fujii Y.
    Mol Clin Oncol; 2014 Sep 15; 2(5):725-730. PubMed ID: 25054037
    [Abstract] [Full Text] [Related]

  • 6. Inhibition of EGFR and MEK surmounts entrectinib resistance in a brain metastasis model of NTRK1-rearranged tumor cells.
    Suzuki C, Nishiyama A, Arai S, Tange S, Tajima A, Tanimoto A, Fukuda K, Takumi Y, Kotani H, Takeuchi S, Yanagimura N, Ohtsubo K, Yamamoto N, Omori K, Yano S.
    Cancer Sci; 2022 Jul 15; 113(7):2323-2335. PubMed ID: 35363931
    [Abstract] [Full Text] [Related]

  • 7. Generating in vitro models of NTRK-fusion mesenchymal neoplasia as tools for investigating kinase oncogenic activation and response to targeted therapy.
    Vanoli F, Herviou L, Tsuda Y, Sung P, Xie Z, Fishinevich E, Min SS, Mallen W, de Wardin HT, Zhang Y, Jasin M, Antonescu CR.
    Oncogenesis; 2023 Feb 17; 12(1):8. PubMed ID: 36801905
    [Abstract] [Full Text] [Related]

  • 8. NTRK Fusion Genes in Thyroid Carcinomas: Clinicopathological Characteristics and Their Impacts on Prognosis.
    Pekova B, Sykorova V, Mastnikova K, Vaclavikova E, Moravcova J, Vlcek P, Lastuvka P, Taudy M, Katra R, Bavor P, Kodetova D, Chovanec M, Drozenova J, Astl J, Hrabal P, Vcelak J, Bendlova B.
    Cancers (Basel); 2021 Apr 16; 13(8):. PubMed ID: 33923728
    [Abstract] [Full Text] [Related]

  • 9. Anti-Tumor Activity of AZD4547 Against NTRK1 Fusion Positive Cancer Cells Through Inhibition of NTRKs.
    Cho H, Kim N, Murakami T, Sim T.
    Front Oncol; 2021 Apr 16; 11():757598. PubMed ID: 34790577
    [Abstract] [Full Text] [Related]

  • 10. Durable Clinical Response to Entrectinib in NTRK1-Rearranged Non-Small Cell Lung Cancer.
    Farago AF, Le LP, Zheng Z, Muzikansky A, Drilon A, Patel M, Bauer TM, Liu SV, Ou SH, Jackman D, Costa DB, Multani PS, Li GG, Hornby Z, Chow-Maneval E, Luo D, Lim JE, Iafrate AJ, Shaw AT.
    J Thorac Oncol; 2015 Dec 16; 10(12):1670-4. PubMed ID: 26565381
    [Abstract] [Full Text] [Related]

  • 11. NTRK fusion cervical sarcoma: a report of three cases, emphasising morphological and immunohistochemical distinction from other uterine sarcomas, including adenosarcoma.
    Rabban JT, Devine WP, Sangoi AR, Poder L, Alvarez E, Davis JL, Rudzinski E, Garg K, Bean GR.
    Histopathology; 2020 Jul 16; 77(1):100-111. PubMed ID: 31971278
    [Abstract] [Full Text] [Related]

  • 12. TRK Inhibition: A New Tumor-Agnostic Treatment Strategy.
    Kummar S, Lassen UN.
    Target Oncol; 2018 Oct 16; 13(5):545-556. PubMed ID: 30276762
    [Abstract] [Full Text] [Related]

  • 13. Design, synthesis, and Structure-Activity Relationships (SAR) of 3-vinylindazole derivatives as new selective tropomyosin receptor kinases (Trk) inhibitors.
    Duan Y, Wang J, Zhu S, Tu ZC, Zhang Z, Chan S, Ding K.
    Eur J Med Chem; 2020 Oct 01; 203():112552. PubMed ID: 32702585
    [Abstract] [Full Text] [Related]

  • 14. From genomic spectrum of NTRK genes to adverse effects of its inhibitors, a comprehensive genome-based and real-world pharmacovigilance analysis.
    Cui Z, Zhai Z, Xie D, Wang L, Cheng F, Lou S, Zou F, Pan R, Chang S, Yao H, She J, Zhang Y, Yang X.
    Front Pharmacol; 2024 Oct 01; 15():1329409. PubMed ID: 38357305
    [Abstract] [Full Text] [Related]

  • 15. Activity of Entrectinib in a Patient With the First Reported NTRK Fusion in Neuroendocrine Cancer.
    Sigal D, Tartar M, Xavier M, Bao F, Foley P, Luo D, Christiansen J, Hornby Z, Maneval EC, Multani P.
    J Natl Compr Canc Netw; 2017 Nov 01; 15(11):1317-1322. PubMed ID: 29118225
    [Abstract] [Full Text] [Related]

  • 16. NTRK Fusions Identified in Pediatric Tumors: The Frequency, Fusion Partners, and Clinical Outcome.
    Zhao X, Kotch C, Fox E, Surrey LF, Wertheim GB, Baloch ZW, Lin F, Pillai V, Luo M, Kreiger PA, Pogoriler JE, Linn RL, Russo PA, Santi M, Resnick AC, Storm PB, Hunger SP, Bauer AJ, Li MM.
    JCO Precis Oncol; 2021 Nov 01; 1():. PubMed ID: 34036219
    [Abstract] [Full Text] [Related]

  • 17. ERK signaling promotes resistance to TRK kinase inhibition in NTRK fusion-driven glioma mouse models.
    Schmid S, Russell ZR, Yamashita AS, West ME, Parrish AG, Walker J, Rudoy D, Yan JZ, Quist DC, Gessesse BN, Alvinez N, Hill KD, Anderson LW, Cimino PJ, Kumasaka DK, Parchment RE, Holland EC, Szulzewsky F.
    Cell Rep; 2024 Oct 22; 43(10):114829. PubMed ID: 39365700
    [Abstract] [Full Text] [Related]

  • 18. Induction of resistance to neurotrophic tropomyosin-receptor kinase inhibitors by HMGCS2 via a mevalonate pathway.
    Kato Y, Matsumoto M, Takano N, Hirao M, Matsuda K, Tozuka T, Onda N, Nakamichi S, Takeuchi S, Miyanaga A, Noro R, Gemma A, Seike M.
    Cancer Med; 2024 Jun 22; 13(12):e7393. PubMed ID: 38923428
    [Abstract] [Full Text] [Related]

  • 19. The potential of neurotrophic tyrosine kinase (NTRK) inhibitors for treating lung cancer.
    Passiglia F, Caparica R, Giovannetti E, Giallombardo M, Listi A, Diana P, Cirrincione G, Caglevic C, Raez LE, Russo A, Rolfo C.
    Expert Opin Investig Drugs; 2016 Jun 22; 25(4):385-92. PubMed ID: 26881293
    [Abstract] [Full Text] [Related]

  • 20. Detection of Tumor NTRK Gene Fusions to Identify Patients Who May Benefit from Tyrosine Kinase (TRK) Inhibitor Therapy.
    Hsiao SJ, Zehir A, Sireci AN, Aisner DL.
    J Mol Diagn; 2019 Jul 22; 21(4):553-571. PubMed ID: 31075511
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.